Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function

Therapeutic Drug Monitoring

Volumn 29, Issue 2, 2007, Pages 261-264

  Tanaka, Akihiro ^a   Suemaru, Katsuya ^a   Otsuka, Takashi ^b   Ido, Keiko ^a   Nishimiya, Tatsuya ^c   Sakai, Ikuya ^d   Hasegawa, Hitoshi ^d   Inoue, Tomoyoshi ^b   Murase, Mitsuharu ^c   Yasukawa, Masaki ^d   Araki, Hiroaki ^a  

^a EHIME UNIVERSITY HOSPITAL   (Japan)

^b Matsuyama Shimin Hospital   (Japan)

^c Division of Laboratory Medicine   (Canada)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Creatinine; Cystatin C; Elderly population; Initial dose setting; Therapeutic drug monitoring; Vancomycin

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; VANCOMYCIN;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CYSTATINS; DRUG MONITORING; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 34248225362     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31803bcfd2     Document Type: Article

References (17)

1. Levey AS, Berg RL, Gassmann JJ, et al. Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int. 1989;36(Suppl 27):S73-S80.
2. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-34.
3. Filler G, Bokenkamp A, Hofmann W, et al. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem. 2005;38:1-8.
4. Cunha BA. Vancomycin. Med Clin N Am. 1995;79:817-831.
5. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25:679-687.
6. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003;26:876-879.
7. Sato M, Shinozaki K, Kojima T, et al. Assessment of three population pharmacokinetic models of vancomycin. Jpn J Ther Drug Monit. 2001;18:286-290.
8. Olusegun AM, Nabila A. Evaluation of cystatin C and b-2 microglobulin as a markers of renal function in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2003;17:160-168.
9. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transpl. 2003;18:2024-2031.
10. Larsson A, Malm J, Grubb A, et al. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest. 2004;64:25-30.
11. Grubb A. Cystatin C: properties and use as diagnostic marker. Adv Clin Chem. 2000;35:63-99.
12. Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20:139-148.
13. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
14. O'Riordan S, Ouldred E, Brice S, et al. Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine. Br J Clin Pharmacol. 2002;53:398-402.
15. Hallberg P, Melhus H, Hansson LO, et al. Cystatin C vs creatinine as markers of renal function in patients on digoxin treatment. Ups J Med Sci. 2004;109:247-53.
16. Finney H, Bates CJ, Price CP. Plasma cystatin C determinations in a healthy elderly population. Arch Gerontol Geriatr. 1999;29:75-94.
17. Hu KT, Matayoshi A, Stevenson FT. Calculation of the estimated creatinine clearance in avoiding drug dosing errors in the older patient. Am J Med Sci. 2001;322:133-136.